AI drug-discovery startup Chai Discovery raises $400 million in Series C, tripling its valuation

Chai Discovery, a startup focused on using artificial intelligence for drug discovery, announced a new Series C financing round that brought in $400 million. The capital injection was led by existing and new investors who aim to support the company’s growth in the AI-driven biotech space.

The fresh funding pushes the company's paper valuation to three times what it was just seven months ago, reflecting strong market confidence in its technology platform. This valuation increase underscores the rapid scaling of AI tools in early-stage drug development.

Industry observers see the deal as a sign that investors are betting heavily on AI to accelerate the discovery of new medicines, and Chai Discovery’s raise positions it among the most well-funded players in the emerging sector.